Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study of Fludarabine, Cytarabine (Ara-C) and Pegylated Erwinase (Pegcrisantaspase) in Patients with Relapsed or Refractory Leukemia

NCT04526795 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04526795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04526795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study of Fludarabine, Cytarabine (Ara-C) and Pegylated Erwinase (Pegcrisantaspase) in Patients with Relapsed or Refractory Leukemia
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
April 9, 2021
Completion date
November 15, 2024
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

blast phase chronic myelogenous leukemia, bcr-abl1 positive, recurrent acute biphenotypic leukemia, recurrent acute lymphoblastic leukemia, recurrent acute myeloid leukemia, recurrent chronic myelogenous leukemia, bcr-abl1 positive, recurrent t-cell prolymphocytic leukemia, refractory acute biphenotypic leukemia, refractory acute lymphoblastic leukemia, refractory acute myeloid leukemia, refractory chronic myelogenous leukemia, bcr-abl1 positive, refractory t-cell prolymphocytic leukemia